Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis
Celine Hernandez, … , Richard A. Friedman, Robert F. Schwabe
Celine Hernandez, … , Richard A. Friedman, Robert F. Schwabe
Published March 20, 2018
Citation Information: J Clin Invest. 2018;128(6):2436-2450. https://doi.org/10.1172/JCI91786.
View: Text | PDF | Expression of Concern | Corrigendum
Research Article Hepatology

HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis

  • Text
  • PDF
Abstract

Cell death is a key driver of disease progression and carcinogenesis in chronic liver disease (CLD), highlighted by the well-established clinical correlation between hepatocellular death and risk for the development of cirrhosis and hepatocellular carcinoma (HCC). Moreover, hepatocellular death is sufficient to trigger fibrosis and HCC in mice. However, the pathways through which cell death drives CLD progression remain elusive. Here, we tested the hypothesis that high-mobility group box 1 (HMGB1), a damage-associated molecular pattern (DAMP) with key roles in acute liver injury, may link cell death to injury responses and hepatocarcinogenesis in CLD. While liver-specific HMGB1 deficiency did not significantly affect chronic injury responses such as fibrosis, regeneration, and inflammation, it inhibited ductular/progenitor cell expansion and hepatocyte metaplasia. HMGB1 promoted ductular expansion independently of active secretion in a nonautonomous fashion, consistent with its role as a DAMP. Liver-specific HMGB1 deficiency reduced HCC development in 3 mouse models of chronic injury but not in a model lacking chronic liver injury. As with CLD, HMGB1 ablation reduced the expression of progenitor and oncofetal markers, a key determinant of HCC aggressiveness, in tumors. In summary, HMGB1 links hepatocyte death to ductular reaction, progenitor signature, and hepatocarcinogenesis in CLD.

Authors

Celine Hernandez, Peter Huebener, Jean-Philippe Pradere, Richard A. Friedman, Robert F. Schwabe

×

Figure 1

HMGB1 is required for ductular reactions.

Options: View larger image (or click on image) Download as PowerPoint
HMGB1 is required for ductular reactions.
(A and B) Eight-week-old mice ...
(A and B) Eight-week-old mice with hepatic deletion of HMGB1 (Hmgb1Δhep, n = 9) had fewer cytokeratin-positive ductular cells (A) and lower expression of Cd133, Afp, and H19 mRNA but similar ALT levels (B) compared with Hmgb1WT/WT control mice (n = 9) in the Tak1Δhep model. (C and D) In the Mdr2KO model, 8-week-old Hmgb1Δhep mice (n = 13) had fewer cytokeratin-positive ductular cells (C) and lower expression of Afp and H19 mRNA but similar ALT levels (E) compared with Hmgb1fl/fl control mice (n = 10). (E and F) After 3 weeks on a DDC diet, Hmgb1Δhep mice (n = 9) had fewer cytokeratin-positive ductular cells (E) and lower expression of Afp and H19 mRNA but similar ALT levels (F) compared with Hmgb1fl/fl control mice (n = 6). (G) Untreated mice (n = 4) and mice treated with 6 injections of CCl4 (n = 11) had similar percentages of cytokeratin-positive cells. HMGB1 serum levels were determined by ELISA in mice that had received (n = 3) or not received (n = 2) 6 injections of CCI. Data are expressed as the mean ± SEM. qPCR data are shown as the fold induction compared with normal liver. *P < 0.05, **P < 0.01, and ***P < 0.001, by unpaired, 2-tailed t test. Scale bars: 100 μm. CK, cytokeratin.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts